Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared ...

Becton, Dickinson and Company has struggled over the past decade, with a 10-year CAGR of only 5.1%. Read what keeps me on the ...

Valued at a market cap of $57.1 billion, Becton, Dickinson and Company (BDX) is a global medical technology company that ...

Shares of Becton Dickinson & Co. BDX shed 1.06% to $196.61 Monday, on what proved to be an all-around dismal trading session ...

Shares of Becton Dickinson & Co. BDX advanced 1.05% to $204.45 Thursday, on what proved to be an all-around positive trading ...

Becton, Dickinson and Company (BD) has received the US Food and Drug Administration’s (FDA) 510(k) clearance for the Phasix ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $260.00.

Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the ...

4 analysts have expressed a variety of opinions on Becton Dickinson BDX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their ...